Sirolimus: all 520 studies that test it

Page 1 of 6. Open to participants first (86), then studies with results posted, then the rest; newest registration first within each.

• Phase I/II Trial of Dinutuximab Beta in Combination With Irinotecan and Rapamycin in Pediatric, Adolescents and Adult Patients With Relapsed/Refractory Bone Tumors.Not yet recruitingNCT07853105Phase 1/2
• Low-Dose Sirolimus for the Treatment of RUNX1 Familial Platelet DisorderRecruitingNCT07844694Phase 1
• A Pilot Study to Examine the Efficacy and Tolerability of Sirolimus on Epidermal Nevi Lesions in Patients 6 Years Old and Above.Not yet recruitingNCT07813533Early Phase 1
• Sirolimus+Ruxolitinib+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to CNINot yet recruitingNCT07796620Phase 1/2
• A Phase 1 Study of UB-VV500 With Rapamycin in Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07735546Phase 1
• A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell MalignanciesRecruitingNCT07735533Phase 1/2
• Effects of Sirolimus on Asymptomatic ApoE4 CarriersRecruitingNCT07728175Phase 1
• Domatinostat With Sirolimus for Relapsed, Refractory Sarcoma and OsteosarcomaRecruitingNCT07725380Phase 1/2
• A Phase 2 Study of Sirolimus for Injection (Albumin-bound) in Patients With Progressive or Symptomatic Epithelioid HemangioendotheliomaNot yet recruitingNCT07684287Phase 2
• Ventricular mTOR Inhibition to Prevent Hydrocephalus After Brain HemorrhageNot yet recruitingNCT07662174Phase 1/2
• Sirolimus in Patients With Systemic Lupus Erythematosus-Associated Immune ThrombocytopeniaRecruitingNCT07657793Phase 2/3
• Low- vs High-Dose Sirolimus With Prednisolone for KHE and KMPRecruitingNCT07656909Phase 2/3
• Vertebrobasilar Dolichoectasia Treatment With SirolimusNot yet recruitingNCT07634120Phase 2
• Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell DiseaseRecruitingNCT07616154Phase 2
• Vaccination Response Modulation With a Targeted Rapamycin Protocol StudyNot yet recruitingNCT07587801Phase 2
• Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple MyelomaRecruitingNCT07581704Phase 1
• Rapamycin Dose-Ranging Efficacy Study in Port Wine StainsNot yet recruitingNCT07436611Phase 2
• Systematic Approach for Children With Orbital Malformation With Sirolimus UseRecruitingNCT07378657Phase 3
• Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic MalignanciesRecruitingNCT07366801Phase 2/3
• A Study Comparing the MAGICTouch™ Sirolimus-coated Balloon With a Paclitaxel-coated Balloon for Treating Severe Narrowing or Blockage in the Femoropopliteal Arteries.Not yet recruitingNCT07359807Phase 2/3
• Gene Replacement Therapy for Treatment of Paediatric Patients With CTNNB1 Neurodevelopmental SyndromeRecruitingNCT07270549Phase 1/2
• Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine TumorsRecruitingNCT07165886Phase 2/3
• Sirolimus Discontinuation Strategies in Kaposiform HemangioendotheliomaRecruitingNCT07131644Phase 2
• Part B- G1X-CGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous DiseaseEnrolling by invitationNCT07113743Phase 1/2
• Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-CessationRecruitingNCT07092618Phase 2/3
• Immunotherapy With Baricitinib and Sirolimus, Alone and in Combination, for the Control of HIV-1 Replication After Antiretroviral Treatment InterruptionNot yet recruitingNCT07081763Phase 2
• Study of ASP2957 in Male Participants With X-linked Myotubular Myopathy Who Need VentilatorsRecruitingNCT07052929Phase 1/2
• Evaluaion the Short Term Effects of Advograf Plus Rapamiune After Kidney TransplantationRecruitingNCT07033858Not applicable
• Low Dose Sirolimus in People With Post-Acute Sequelae of COVID-19 (PASC) Long COVID-19RecruitingNCT06960928Phase 3
• Base Editing Hematopoietic Stem Cell and T Cell Gene Therapy for CD40L-HyperIgM Syndrome: Single Patient StudyRecruitingNCT06959771Phase 1/2
• A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast CancerNot yet recruitingNCT06941142Phase 1
• Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 InhibitorsNot yet recruitingNCT06929325Phase 3
• Allo HSCT for High Risk HemoglobinopathiesRecruitingNCT06872333Phase 2
• A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast CancerRecruitingNCT06856200Not applicable
• Sirolimus for Leigh SyndromeEnrolling by invitationNCT06843811Phase 2
• UB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell MalignanciesRecruitingNCT06743503Phase 1
• Sirolimus Monotherapy in the Treatment of Antiphospholipid Antibody Related ThrombocytopeniaRecruitingNCT06722586Phase 4
• Sirolomus Adjuvant Treatment of Focal Refractory Epilepsy (SATFRE)RecruitingNCT06719791Early Phase 1
• A Nutritional and Pharmacological Intervention for Body, Brain, and Longevity Effects (NIBBLE)Not yet recruitingNCT06682767Phase 1/2
• Different Doses of Sirolimus for the Treatment of Cystic Lymphatic MalformationsRecruitingNCT06673290Phase 2/3
• RESTOR: PK/PD mTORi Inhibition in Older AdultsRecruitingNCT06658093Early Phase 1
• The Safety and Efficacy of Rapamycin on Communicating Hydrocephalus Secondary to Intraventricular HemorrhageRecruitingNCT06563817Phase 2
• A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell MalignanciesRecruitingNCT06528301Phase 1
• The Safety and Efficiency of Sirolimus in Primary Antiphospholipid Syndrome: a Randomized Control StudyNot yet recruitingNCT06504420Phase 2
• Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous DiseaseRecruitingNCT06325709Phase 1/2
• Safety Study for the Use of Rapamycin in Children With Familial Adenomatous PolyposisNot yet recruitingNCT06308445Phase 2
• Sirolimus+Abatacept+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to Calcineurin InhibitorsNot yet recruitingNCT06279494Phase 1/2
• Low-Dose Sirolimus to Increase Hematopoietic Function in Patients With RUNX1 Familial Platelet DisorderRecruitingNCT06261060Phase 2
• The Effects of Sirolimus in Patients With Dilated Cardiomyopathy Infected With Kaposi Sarcoma-associated VirusRecruitingNCT06236022Phase 4
• Hemorrhagic Brainstem Cavernous Malformations Treatment With Sirolimus: aSingle Centre, Randomized, Placebo-controlled Pilot TrialRecruitingNCT06091332Phase 2
• Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE)Not yet recruitingNCT06084780Phase 2
• Advancing Transplantation Outcomes in ChildrenRecruitingNCT06055608Phase 2
• Rapalog Pharmacology (RAP PAC) StudyRecruitingNCT05949658Phase 1
• Sirolimus in the Treatment of Refractory/Relapsed wAIHARecruitingNCT05925023Not applicable
• Venetoclax Combined With Azactidine in the Treatment of ALALRecruitingNCT05901974Phase 2
• Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin CancerRecruitingNCT05896839Phase 1/2
• Study of Sirolimus in IgG4-related DiseaseNot yet recruitingNCT05746689Not applicable
• Efficacy and Safety of Sirolimus in Children and Adolescents With Juvenile Nasopharyngeal Angiofibroma (JNA)RecruitingNCT05549167Phase 3
• Sirolimus in Cutaneous SarcoidosisNot yet recruitingNCT05458492Phase 2
• The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell TransplantationRecruitingNCT05436418Phase 1/2
• Thal-Fabs: Reduced Toxicity Conditioning for High Risk ThalassemiaRecruitingNCT05426252Phase 1/2
• Impacts of Mechanistic Target of Rapamycin (mTOR) Inhibition on Aged Human Muscle (Rapamune)RecruitingNCT05414292Not applicable
• Different Doses of Sirolimus for the Maintenance Treatment of Kaposiform HemangioendotheliomaRecruitingNCT05324384Phase 2
• The Role of Sirolimus in Preventing Functional Decline in Older AdultsRecruitingNCT05237687Phase 2
• mTOR as Mediator of Insulin Sensitivity StudyRecruitingNCT05233722Not applicable
• Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention StudyRecruitingNCT05104983Phase 2
• COAST Therapy in Advanced Solid Tumors and Prostate CancerRecruitingNCT05036226Phase 1/2
• Efficacy and Safety of Rapamycin Versus Vigabatrin in the Prevention of Tuberous Sclerosis Complex Symptoms in InfantsRecruitingNCT04987463Phase 2/3
• Sirolimus vs Corticosteroids in Treatment of Thyroid Eye DiseaseRecruitingNCT04936854Phase 2
• Percutaneous Administration of Sirolimus in the Treatment of Superficial Complicated Vascular AnomaliesRecruitingNCT04921722Phase 4
• Methods of T Cell Depletion Trial (MoTD)RecruitingNCT04888741Phase 2
• Weekly Sirolimus TherapyRecruitingNCT04861064Phase 2
• Sirolimus Treatment Of Patients With SLENot yet recruitingNCT04736953Phase 2
• Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM PathwayNot yet recruitingNCT04736589Phase 3
• Sirolimus for Graves' Orbitopathy (GO)Not yet recruitingNCT04598815Phase 2
• Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid TumorsRecruitingNCT04469530Phase 2
• Sirolimus in the Treatment for Infantile Hepatic Hemangioendothelioma(IEEH)Not yet recruitingNCT04406870Phase 4
• A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 GangliosidosisRecruitingNCT03952637Phase 1/2
• Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell DiseaseRecruitingNCT03587272Phase 2
• The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant RecipientsEnrolling by invitationNCT03292861Phase 2
• Efficacy of Rapamycin in the Treatment of Cervico-facial Lymphatic MalformationsRecruitingNCT03243019Phase 2
• Nonmyeloablative Stem Cell Transplant in Children With Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling DonorRecruitingNCT03214354Phase 2
• Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell DiseaseRecruitingNCT03121001Phase 2
• Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid CancerRecruitingNCT03099356Phase 2
• Efficacy and Safety of Sirolimus in Vascular Anomalies That Are Refractory to Standard CareRecruitingNCT02638389Phase 3
• Prospective Evaluation of the Efficacy of Sirolimus (Rapamune®) in the Treatment of Severe Arteriovenous MalformationsRecruitingNCT02042326Phase 2
• Non-myeloablative Haploidentical HCT Study for Patients With Sickle Cell Disease, Including Compromised Organ FunctionActive, not recruitingNCT06145282Phase 1/2Results posted
• A Study Testing the Use of a Perivascular Sirolimus Formulation (Sirogen) in ESRD Patients Undergoing AV Fistula SurgeryCompletedNCT05425056Phase 3Results posted
• Sirolimus for Nosebleeds in HHTCompletedNCT05269849Phase 2Results posted
• Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC InfantsCompletedNCT04595513Phase 1/2Results posted
• Study to Evaluate the Efficacy and Safety of Sirolimus in Subjects With Metastatic, Mismatch Repair Deficient Solid Tumors After ImmunotherapyTerminatedNCT04393454Phase 2Results posted
• Sirolimus and Durvalumab for the Treatment of Stage I-IIIA Non-small Cell Lung CancerTerminatedNCT04348292Phase 1Results posted
• Sirolimus Treatment in Hospitalized Patients With COVID-19 PneumoniaCompletedNCT04341675Phase 2Results posted
• Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell TransplantationCompletedNCT04339101Phase 2Results posted
• Cognition, Age, and RaPamycin Effectiveness - DownregulatIon of thE mTor PathwayCompletedNCT04200911Early Phase 1Results posted
• Enhancing Self Regulation Among SmokersCompletedNCT04161144Phase 2Results posted
• RAPA-Keloid Study of Keloid RegressionCompletedNCT04049552Early Phase 1Results posted
• Sirolimus in Previously Treated Idiopathic Multicentric Castleman DiseaseActive, not recruitingNCT03933904Phase 2Results posted
• Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis ComplexCompletedNCT03826628Phase 2/3Results posted
• Altering Memories That Increase Risk of Relapse in Alcohol Use DisordersCompletedNCT03732248Phase 1Results posted

← Sirolimus overview